Medical Doctor Program year 2025 Reported 2024–2025 Source: CMS Open Payments, 2026 publication

Steven Rowe

Urology Middletown, NY Medical Doctor

NPI 1164416897 CMS profile 143799

95 Crystal Run Rd, Middletown, NY 10941

Open in the dashboard

General payments

$239

3 records reported · program years 2024–2025

Research payments

$0

Paid to them · None reported · program years 2024–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$199,802 paid to institutions, not to them · program years 2022–2025

Through program year 2025, Steven Rowe of Middletown, NY is reported in the CMS Open Payments database as having received $239 across 3 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $199,802 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 16th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $103 1
2024 General $135 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Rowe
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Steven Rowe were reported at $103. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Steven Rowe Urology median Middle half National median
2019 $0 $480 $147–$1,201 $163
2020 $0 $246 $87–$645 $114
2021 $0 $358 $111–$1,000 $132
2022 $0 $476 $143–$1,263 $149
2023 $0 $560 $168–$1,461 $160
2024 $135 $563 $170–$1,464 $164
2025 $103 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2024–2025
  1. Ambu Inc. $103 1 payment
  2. Bioprotect Medical, Inc. $92 1 payment
  3. PROCEPT BioRobotics Corporation $43 1 payment

Every payment, record by record

What the payments were for General payments · program years 2024–2025
  1. Food and Beverage $239 3 payments
Products named General payments · program years 2024–2025
  1. BIOPROTECT BALLOON IMPLANT SYSTEM $92 1 payment
  2. AQUABEAM SYSTEM $43 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

3,465

Median for Urology: 1,053

Drug cost

$230,869

Median for Urology: $101,464

Branded share of claims

28.2%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 202 $119,888
Gemtesa Vibegron Brand 58 $33,568
Tamsulosin Hcl Generic 1,370 $19,216
Potassium Citrate Er Potassium Citrate Brand 119 $8,739
Oxybutynin Chloride Er Oxybutynin Chloride Brand 327 $8,505
Estradiol Generic 67 $6,623
Finasteride Generic 562 $6,071
Testosterone Generic 23 $4,606
Tadalafil Generic 39 $3,136
Tolterodine Tartrate Er Tolterodine Tartrate Brand 32 $2,993

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 119 billing codes

Paid by Medicare

$317,753

Of which drugs: $20,180

Medicare patients

1,110

Average age 74

Services billed

8,010

220 women, 890 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Ischemic heart disease 42%
Diabetes 33%
Chronic kidney disease 31%
Cancer 27%
COPD 24%
Atrial fibrillation 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 20 112 $15,892

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

3 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record